MORDOR II Burkina Faso: Longitudinal Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

July 6, 2020

Study Completion Date

July 6, 2020

Conditions
Child GrowthDiversity of MicrobiomeChild MortalityResistance Bacterial
Interventions
DRUG

Azithromycin

Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.

DRUG

Placebo

Oral suspension of placebo for azithromycin

Trial Locations (1)

Unknown

Centre de Recherche en Sante de Nouna, Nouna

All Listed Sponsors
collaborator

Centre de Recherche en Sante de Nouna, Burkina Faso

OTHER_GOV

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of California, San Francisco

OTHER

NCT03676751 - MORDOR II Burkina Faso: Longitudinal Trial | Biotech Hunter | Biotech Hunter